Загрузка...
Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38
BACKGROUND: Widely established targeted therapies directed at triple negative breast cancer (TNBC) are missing. Classical chemotherapy remains the systemic treatment option. Cisplatin has been tested in TNBC but bears the disadvantage of resistance development. The purpose of this study was to ident...
Сохранить в:
| Опубликовано в: : | BMC Cancer |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5670521/ https://ncbi.nlm.nih.gov/pubmed/29100507 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3695-5 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|